Xynomic pharmaceuticals holdings, inc. (XYN)
Income statement / Yearly
Dec'18Dec'17
Operating expenses:
Total operating expenses

835

365

Loss from operations

-835

-365

Interest income

1,121

341

Unrealized loss on marketable securities held in Trust Account

-19

-17

Net loss

266

-41

Other comprehensive income/(loss):
Weighted average ordinary shares outstanding - basic and diluted

2,426

1,870

Basic and diluted net income (loss) per ordinary share

-0.30

-0.18